Company: EDSA
Filing Date: 2025-08-08
Form Type: 10-Q
Source: 0001171843-25-005236
Chunk: 100

Company: Edesa Biotech, Inc.
Filing Date: 2025-08-08
Form: 10-Q
Item: Part II, Item 4
Chunk 100
---
Not applicable.

Item 5. Other Information.

None of the Company's directors and officers adopted, modified, or terminated a Rule 10b-1 trading arrangement or a non-Rule 10b5-1 trading arrangement during the Company's fiscal quarter ended June 30, 2025 (each as defined in Item 408 of Regulation S-K under the Securities Exchange Act of 1934, as amended).

26

Item 6. Exhibits

EXHIBIT INDEX

			Exhibit No.

			Description 

			10.1 ^
			 
			Employment Agreement, dated April 3, 2025, by and between the Company and Peter Weiler (included as Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed on April 4, 2025, and incorporated herein by reference).

			10.2 ^
			 
			Consulting Agreement, dated May 12, 2025, by and between Edesa Biotech Research, Inc. and Stephen Lemieux (included as Exhibit 10.4 to the Company’s Quarterly Report on Form 10-Q, filed on May 14, 2025, and incorporated herein by reference)

			10.3 ^
			 
			Amendment No. 4 to Edesa Biotech, Inc. 2019 Equity Incentive Compensation Plan (included as Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed on May 28, 2025, and incorporated herein by reference).

			31.1

			Certification of the Chief Executive Officer pursuant to Rule 13a-14(a) under the Securities and Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).

			31.2

			Certification of the Chief Financial Officer pursuant to Rule 13a-14(a) under the Securities and Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).

			32.1*

			Certification of the Chief Executive Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (filed herewith).

			32.2*

			Certification of the Chief